The unaudited financial statements for the Q2FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
Key Consolidated Financial Highlights for Q2FY25:
|
Particulars |
Q2 FY25 |
Q2 FY24 |
Y-o-Y |
|
Revenues (in Rs Cr) |
Rs. 166.1 |
Rs. 140.1 |
18.6% |
|
Gross Profit (in Rs Cr) |
Rs. 120.13 |
Rs.78.46 |
53.1% |
|
EBITDA (in Rs Cr) |
Rs. 64.72 |
Rs. 31.75 |
103.8% |
|
EBITDA Margin |
39.0% |
22.7% |
+1630 Bps |
|
PAT (in RsCr) |
Rs. 46.15 |
Rs. 23.88 |
93.2% |
|
PAT Margin |
27.8% |
17.0% |
+1074 Bps |
|
EPS (in Rs) |
5.71 |
2.97 |
|
Key Consolidated Financial Highlights for H1FY25:
|
Particulars |
H1 FY25 |
H1 FY24 |
Y-o-Y |
|
Revenues (in Rs Cr) |
Rs. 326.7 |
Rs. 272.1 |
20.1% |
|
Gross Profit (in Rs Cr) |
Rs. 232.1 |
Rs.163.2 |
42.2% |
|
EBITDA (in Rs Cr) |
Rs. 127.2 |
Rs. 75.9 |
67.5% |
|
EBITDA Margin |
38.9% |
27.9% |
+1103 Bps |
|
PAT (in RsCr) |
Rs. 907.9 |
Rs. 523.9 |
73.3% |
|
PAT Margin |
27.8% |
19.3% |
+853 Bps |
|
EPS (in Rs) |
11.25 |
6.51 |
|
Key Highlights for Q2 FY25:
- In the second quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 18.6 % year-over-year increase, reaching Rs. 166.1 crore compared to Rs. 140.1 crore in Q2 FY24
- Gross Profit for Q2 FY25 stood at Rs. 120.13 crore, with a growth of 53.1% compared to Rs. 78.46 crore in Q2 FY24
- EBITDA for Q2 FY25 stood at Rs. 64.72 crore, with an EBITDA Margin of 39.0%, as opposed to an EBITDA of Rs. 31.75 crore in Q2 FY24 with an EBITDA margin of 22.7%. This marks a growth of 103.8% YoY
- The Profit After Tax (PAT) for Q2 FY25 came at Rs 46.15 crore, compared to Rs 23.88 crore in Q2 FY24
- The PAT Margin stood at 27.8% in Q2 FY25, compared to 17.0% in Q2 FY24
- Analgesic and Anaesthetic segment led the business growth in Q2 contributing 54.9% to the revenue vs 50.0% in Q2FY24. Anti-Asthmatic segment contributed 9.2% compared to 7.2%
- European markets now contribute 45% of our business revenue in H1FY25 up from 39% in H1FY24
- For Anaesthetic therapy 3 ANDA projects have been initiated and company is also working on ANDA projects for Anti Hypertensive and Vitamins
- Capacity Utilisation has quickly increased from 47% in FY22 following a fresh capacity addition to 86% in FY24. In order to support future growth of various business segments the company has acquired three separate land parcels near different plants
- Supriya Lifescience Ltd. continues to expand its global footprint, now doing business with over 1,700 customers across more than 128 countries. To ensure sustained growth and further expansion through new customer acquisition, the company has strategically distributed these geographic regions among its dedicated sales teams
Dr. Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd, commenting on the results, said, “Our commitment to innovation through R&D is paving the way for sustained growth and expansion. With the commissioning of our advanced R&D lab at Lote Parshuram and the upcoming Ambernath facility, we’re focusing on new product development and CMO/CDMO opportunities to complement our existing portfolio. Expanding our global presence across key regions, we're also working closely with regulatory and sales teams to acquire new customers, particularly in regulated markets. Our recent exclusive 10-year contract with a leading European firm underscores our capabilities in handling complex chemical processes, setting the stage for similar opportunities. As we enhance our infrastructure, including increasing capacity at Lote Parshuram to 1,020 KL by Q3 FY25, we’re building a foundation for a stronger future.”
